S&P 500   3,197.52 (+1.34%)
DOW   26,642.59 (+2.13%)
QQQ   260.37 (+0.71%)
AAPL   388.23 (+1.65%)
MSFT   208.35 (+0.62%)
FB   239.73 (+0.31%)
GOOGL   1,520.86 (+0.57%)
AMZN   3,084.00 (-0.64%)
NVDA   415.08 (+3.23%)
CGC   17.38 (+0.46%)
BABA   248.58 (-1.23%)
MU   49.71 (+0.51%)
GE   6.88 (+2.69%)
TSLA   1,516.80 (+1.32%)
AMD   54.72 (+2.11%)
T   29.96 (+0.64%)
ACB   11.75 (-2.73%)
F   6.36 (+4.78%)
GILD   77.19 (+0.67%)
DIS   118.66 (+2.08%)
NFLX   524.88 (-0.12%)
BAC   24.14 (-0.21%)
BA   179.96 (+2.45%)
S&P 500   3,197.52 (+1.34%)
DOW   26,642.59 (+2.13%)
QQQ   260.37 (+0.71%)
AAPL   388.23 (+1.65%)
MSFT   208.35 (+0.62%)
FB   239.73 (+0.31%)
GOOGL   1,520.86 (+0.57%)
AMZN   3,084.00 (-0.64%)
NVDA   415.08 (+3.23%)
CGC   17.38 (+0.46%)
BABA   248.58 (-1.23%)
MU   49.71 (+0.51%)
GE   6.88 (+2.69%)
TSLA   1,516.80 (+1.32%)
AMD   54.72 (+2.11%)
T   29.96 (+0.64%)
ACB   11.75 (-2.73%)
F   6.36 (+4.78%)
GILD   77.19 (+0.67%)
DIS   118.66 (+2.08%)
NFLX   524.88 (-0.12%)
BAC   24.14 (-0.21%)
BA   179.96 (+2.45%)
S&P 500   3,197.52 (+1.34%)
DOW   26,642.59 (+2.13%)
QQQ   260.37 (+0.71%)
AAPL   388.23 (+1.65%)
MSFT   208.35 (+0.62%)
FB   239.73 (+0.31%)
GOOGL   1,520.86 (+0.57%)
AMZN   3,084.00 (-0.64%)
NVDA   415.08 (+3.23%)
CGC   17.38 (+0.46%)
BABA   248.58 (-1.23%)
MU   49.71 (+0.51%)
GE   6.88 (+2.69%)
TSLA   1,516.80 (+1.32%)
AMD   54.72 (+2.11%)
T   29.96 (+0.64%)
ACB   11.75 (-2.73%)
F   6.36 (+4.78%)
GILD   77.19 (+0.67%)
DIS   118.66 (+2.08%)
NFLX   524.88 (-0.12%)
BAC   24.14 (-0.21%)
BA   179.96 (+2.45%)
S&P 500   3,197.52 (+1.34%)
DOW   26,642.59 (+2.13%)
QQQ   260.37 (+0.71%)
AAPL   388.23 (+1.65%)
MSFT   208.35 (+0.62%)
FB   239.73 (+0.31%)
GOOGL   1,520.86 (+0.57%)
AMZN   3,084.00 (-0.64%)
NVDA   415.08 (+3.23%)
CGC   17.38 (+0.46%)
BABA   248.58 (-1.23%)
MU   49.71 (+0.51%)
GE   6.88 (+2.69%)
TSLA   1,516.80 (+1.32%)
AMD   54.72 (+2.11%)
T   29.96 (+0.64%)
ACB   11.75 (-2.73%)
F   6.36 (+4.78%)
GILD   77.19 (+0.67%)
DIS   118.66 (+2.08%)
NFLX   524.88 (-0.12%)
BAC   24.14 (-0.21%)
BA   179.96 (+2.45%)
Log in

CVE:LXGLexagene Stock Price, Forecast & News

Add
Compare
Today's Range N/A
50-Day Range
C$0.73
MA: C$0.84
C$0.98
52-Week Range N/A
Volume202,600 shs
Average Volume221,864 shs
Market CapitalizationC$83.27 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
LexaGene Holdings Inc., a biotechnology company, engages in the research, development, and commercialization of automated pathogen detection platform in the life sciences and diagnostics industries. The company's platform is used at the site of sample collection, which offers unprecedented ease-of-use, sensitivity, and breadth of pathogen detection. Its technology aims to transform the way organizations prevent and diagnose disease in various markets, such as food safety, veterinary diagnostics, water quality monitoring, aquaculture pathogen surveillance, and more. The company is headquartered in Beverly, Massachusetts.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.50 out of 5 stars


Industry, Sector and Symbol

Industry Diagnostics & Research
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone800-215-1824

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book ValueC$0.04 per share

Profitability

Miscellaneous

Employees20
Market CapC$83.27 million
Next Earnings DateN/A
OptionableNot Optionable

Receive LXG News and Ratings via Email

Sign-up to receive the latest news and ratings for LXG and its competitors with MarketBeat's FREE daily newsletter.

Lexagene (CVE:LXG) Frequently Asked Questions

Has Lexagene been receiving favorable news coverage?

News coverage about LXG stock has trended somewhat negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Lexagene earned a news sentiment score of -1.5 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news about Lexagene.

Who are some of Lexagene's key competitors?

What other stocks do shareholders of Lexagene own?

Who are Lexagene's key executives?

Lexagene's management team includes the following people:
  • Dr. John F. Regan, Founder, Chairman & CEO
  • Mr. Darrel M. Rebeck, Pres & Director
  • Mr. Jeffrey Mitchell, Chief Financial Officer
  • Mr. Allan Fabbro, VP of Corp. Devel.

What is Lexagene's stock symbol?

Lexagene trades on the Canadian Venture Exchange (CVE) under the ticker symbol "LXG."

How do I buy shares of Lexagene?

Shares of LXG and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

How big of a company is Lexagene?

Lexagene has a market capitalization of C$0.00. Lexagene employs 20 workers across the globe.

What is Lexagene's official website?

The official website for Lexagene is www.lexagene.com.

How can I contact Lexagene?

The company can be reached via phone at 800-215-1824.

This page was last updated on 7/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.